Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Luc+-NSCs are neural stem cells (NSCs) genetically modified to express the firefly luciferase enzyme, serving as a bioluminescent reporter for in vivo tracking. These cells are utilized in preclinical research to monitor the survival, migration, and integration of engrafted stem cells within the central nervous system using non-invasive bioluminescent imaging (BLI). In the context of amyotrophic lateral sclerosis (ALS), Luc+-NSCs have been studied in SOD1G93A mouse models to investigate how the disease's hostile spinal cord microenvironment, characterized by astrogliosis and microgliosis, impacts the longevity of transplanted cells. While they may offer transient functional benefits, their primary utility in these studies is to provide longitudinal data on cell viability post-transplantation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Luc+-NSCs.